Robert CantoneCo-Chair, Life Sciences Transactional Group at Proskauer Rose LLP
Robert is a corporate lawyer and Co-Chair of the firm’s Life Sciences Transactional Group. He advises clients on a broad range of transactional, corporate governance and disclosure matters. His practice is broad-based, with particular emphasis on the representation of public companies in the life sciences sector. His transactional practice focuses on mergers and acquisitions and strategic
alliances structured to advance innovative technologies. Working with management teams and boards of directors, Robert also
advises on corporate governance policies, as well as matters relating to activist defense. Robert advises clients on public disclosures regarding a range of important corporate developments.
Illustrative client matters include:
$9.0 billion acquisition of Juno Therapeutics, Inc.
> $7.2 billion acquisition of Receptos, Inc.
> $2.9 billion acquisition of Pharmion Corporation
> $1.9 billion sale of Andrx Corporation
> $600 million acquisition of EngMab AG
> $300 million acquitision of Delinia, Inc.
> Acquisition of pharmaceutical product portfolio from Novartis Pharma AG
by Mereo BioPharma Group Ltd
> Acquisition of product rights by Braeburn Pharmaceuticals
> Strategic investments, collaborations and options to acquire involving:
> Acetylon Pharmaceuticals, Inc. > Lycera Corp.
> Alliqua BioMedical > Nimbus Therapeutics, Inc.
> Crispr Therapeutics AG > Northern Biologics Inc.
> EngMab AG > Skyhawk Therapeutics, Inc.
> Human Longevity, Inc. > VAXON Biotech SA
> Inception IBD, Inc. > VentiRx Pharmaceuticals